Carlos Cordon-Cardo, MD, PhD Named Chair of Department of Pathology at The Mount Sinai Medical Center
Dr. Cordon-Cardo, an expert in experimental pathology and molecular oncology, joins Mount Sinai as Chair of the Department of Pathology.
Carlos Cordon-Cardo, MD, PhD, a renowned physician-scientist known widely for his research in experimental pathology and molecular oncology, has joined The Mount Sinai Medical Center as Chair of the Department of Pathology. His appointment begins Friday, April 1.
A distinguished leader in the mechanism of tumor suppression, Dr. Cordon-Cardo’s research has focused on analyses of multidrug resistance and alterations of tumor suppressor genes in human cancer. He pioneered the development and implementation of an oncologic molecular pathology discipline, and recently he participated in the creation of the "systems pathology" platform, which uses systems biology to create mathematical models of interaction and behavior of cancer cells to determine tumor pathogenesis and clinical outcome.
"Mount Sinai is at the forefront in discovery and innovation in cancer research, and Dr. Cordon-Cardo is ideally suited in furthering our mission," said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs at The Mount Sinai Medical Center. "I am pleased he is joining the institution at such an important time, and am confident he will continue the momentum to have a lasting impact in translational cancer medicine."
Dr. Cordon-Cardo will draw upon his experience as an outstanding investigator, administrator and educator to bring the Department of Pathology to the next level of accomplishment. His vision for enhancing both clinical and research programs will strengthen and grow this mission-critical department.
Dr. Cordon-Cardo’s contributions to cancer research thus far have had important implications for tumor suppression, particularly in bladder cancer, prostate cancer, and soft tissue sarcomas. His current agenda is aimed at understanding the cooperative effects of mutations of cell-cycle regulation, and genes that prevent cell death cancer. He is also developing and characterizing animal models for loss of function of specific pathways by targeted gene disruption using bladder cancer and sarcomas. More recently, studies from his laboratory have linked adult stem cells and cancer, revealing that certain tumors originate from distinct differentiation stages in stem cell fate and development.
After completing medical school at the Autonomous University of Barcelona in Spain, Dr. Cordon-Cardo earned his PhD in Cell Biology and Genetics from Cornell University Medical College. From 1987 to 2006, he was a faculty member in the Department of Pathology at Memorial Sloan-Kettering Cancer Center, where he created the Division of Molecular Pathology in 1995. He joins Mount Sinai from Columbia University College of Physicians and Surgeons, where he conducted his research and served as Vice-Chair of Pathology, Professor of Pathology and Urology, and Associate Director for Infrastructure at the Herbert Irving Comprehensive Cancer Center, a position he held since 2006.
A highly cited author, Dr. Cordon-Cardo has National Cancer Institute funding for his research, numerous patents, and is a dedicated mentor. He also holds prominent posts in numerous national and international professional organizations.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. U.S. News & World Report consistently ranks The Mount Sinai Hospital among the nation's best hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.